ORKA

The 8-K filing confirms that Oruka Therapeutics has successfully navigated its annual meeting with all primary proposals passing. While the bull case views this as a clean slate for execution, the bear case highlights the presence of non-votes and specific dissent as indicators of latent risk. Ultimately, the filing establishes a baseline of governance stability, but the true test for investors will be whether this mandate translates into tangible clinical milestones or is merely a prelude to capital raises.

The Q1 2026 filing presents a company at a critical juncture, balancing a newly fortified balance sheet against the inherent volatility of clinical-stage drug development. The successful April offering has provided the necessary runway to execute its ambitious pipeline goals, but the increasing operational costs highlight the capital-intensive nature of its pursuit of category-defining therapies. Ultimately, the investment thesis hinges on whether Oruka can convert its promising Phase 2a data and strategic partnerships into a commercially viable product. The upcoming data from the EVERLAST-B and ORCA-SURGE trials will be the definitive catalysts, determining if the company's half-life extension technology can truly disrupt the established psoriasis market or if it remains a high-cost experiment in antibody engineering.